Comparative Pharmacology
Head-to-head clinical analysis: TALWIN 50 versus ULTIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TALWIN 50 versus ULTIVA.
TALWIN 50 vs ULTIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pentazocine is a mixed agonist-antagonist opioid analgesic with activity at kappa opioid receptors (agonist) and mu opioid receptors (partial agonist/antagonist). It also exhibits weak antagonistic activity at mu receptors, which reduces abuse liability but may precipitate withdrawal in opioid-dependent patients.
Selective mu-opioid receptor agonist with rapid onset and short duration of action; produces analgesia without significant histamine release.
50 mg orally every 3-4 hours as needed; maximum 600 mg per day.
IV bolus: 1 mcg/kg over 30-60 seconds, then continuous IV infusion: 0.25-1 mcg/kg/min for intraoperative analgesia. For general anesthesia induction: 0.5-1 mcg/kg IV bolus; maintenance: 0.25-1 mcg/kg/min IV infusion.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours. In patients with hepatic impairment, half-life may extend to 5-8 hours; in renal impairment, minimal change, but active metabolite accumulation may occur.
Terminal elimination half-life is 3-10 minutes (context-sensitive half-time is 3-4 minutes independent of infusion duration due to rapid ester hydrolysis). Clinically, recovery is rapid and predictable even after prolonged infusions, with full recovery within 5-10 minutes of discontinuation.
Primarily renal (60-70% as unchanged drug and conjugates), with 20-30% biliary/fecal elimination. Approximately 5-10% excreted in feces via bile.
Remifentanil is metabolized by non-specific blood and tissue esterases to a virtually inactive metabolite (remifentanil acid, 1/4600 potency). Renal excretion accounts for approximately 90% of the metabolite; fecal elimination is minimal (<5%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic